104 related articles for article (PubMed ID: 25077680)
1. EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.
Fu Y; Chen J; Pang B; Li C; Zhao J; Shen K
Cell Biochem Biophys; 2015 Jan; 71(1):105-12. PubMed ID: 25077680
[TBL] [Abstract][Full Text] [Related]
2. Morphological Changes Induced by TKS4 Deficiency Can Be Reversed by EZH2 Inhibition in Colorectal Carcinoma Cells.
Jacksi M; Schad E; Tantos A
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672463
[TBL] [Abstract][Full Text] [Related]
3. Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma.
Xie CR; Li Z; Sun HG; Wang FQ; Sun Y; Zhao WX; Zhang S; Zhao WX; Wang XM; Yin ZY
Oncotarget; 2015 Dec; 6(38):40940-52. PubMed ID: 26517514
[TBL] [Abstract][Full Text] [Related]
4. H3K27me3 is an Epigenetic Mark of Relevance in Endometriosis.
Colón-Caraballo M; Monteiro JB; Flores I
Reprod Sci; 2015 Sep; 22(9):1134-42. PubMed ID: 25820690
[TBL] [Abstract][Full Text] [Related]
5. EZH2: a novel target for cancer treatment.
Duan R; Du W; Guo W
J Hematol Oncol; 2020 Jul; 13(1):104. PubMed ID: 32723346
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of action and resistance in histone methylation-targeted therapy.
Yamagishi M; Kuze Y; Kobayashi S; Nakashima M; Morishima S; Kawamata T; Makiyama J; Suzuki K; Seki M; Abe K; Imamura K; Watanabe E; Tsuchiya K; Yasumatsu I; Takayama G; Hizukuri Y; Ito K; Taira Y; Nannya Y; Tojo A; Watanabe T; Tsutsumi S; Suzuki Y; Uchimaru K
Nature; 2024 Mar; 627(8002):221-228. PubMed ID: 38383791
[TBL] [Abstract][Full Text] [Related]
7. Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader.
Yu X; Wang J; Gong W; Ma A; Shen Y; Zhang C; Liu X; Cai L; Liu J; Wang GG; Jin J
Oncogene; 2023 Mar; 42(13):994-1009. PubMed ID: 36747009
[TBL] [Abstract][Full Text] [Related]
8. LncRNA H19-EZH2 interaction promotes liver fibrosis via reprogramming H3K27me3 profiles.
Li XJ; Zhou F; Li YJ; Xue XY; Qu JR; Fan GF; Liu J; Sun R; Wu JZ; Zheng Q; Liu RP
Acta Pharmacol Sin; 2023 Dec; 44(12):2479-2491. PubMed ID: 37580495
[TBL] [Abstract][Full Text] [Related]
9. CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity.
Karakashev S; Zhu H; Wu S; Yokoyama Y; Bitler BG; Park PH; Lee JH; Kossenkov AV; Gaonkar KS; Yan H; Drapkin R; Conejo-Garcia JR; Speicher DW; Ordog T; Zhang R
Nat Commun; 2018 Feb; 9(1):631. PubMed ID: 29434212
[TBL] [Abstract][Full Text] [Related]
10. 3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells.
Girard N; Bazille C; Lhuissier E; Benateau H; Llombart-Bosch A; Boumediene K; Bauge C
PLoS One; 2014; 9(5):e98176. PubMed ID: 24852755
[TBL] [Abstract][Full Text] [Related]
11. Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro.
Shen JK; Cote GM; Gao Y; Choy E; Mankin HJ; Hornicek FJ; Duan Z
Sci Rep; 2016 Apr; 6():25239. PubMed ID: 27125524
[TBL] [Abstract][Full Text] [Related]
12. EZH2 Contributes to Anoikis Resistance and Promotes Epithelial Ovarian Cancer Peritoneal Metastasis by Regulating m6A.
Wang SH; Liu L; Bao KY; Zhang YF; Wang WW; Du S; Jia NE; Suo S; Cai J; Guo JF; Lv G
Curr Med Sci; 2023 Aug; 43(4):794-802. PubMed ID: 37498408
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of EZH2 primes the cardiac gene activation via removal of epigenetic repression during human direct cardiac reprogramming.
Tang Y; Zhao L; Yu X; Zhang J; Qian L; Jin J; Lu R; Zhou Y
Stem Cell Res; 2021 May; 53():102365. PubMed ID: 34087994
[TBL] [Abstract][Full Text] [Related]
14. Role of EZH2 in adipogenesis and obesity: Current state of the art and implications - A review.
Wang H
Medicine (Baltimore); 2022 Sep; 101(36):e30344. PubMed ID: 36086687
[TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to DZNep-mediated apoptosis is associated with copy number gains of AHCY in a B-cell lymphoma model.
Akpa CA; Kleo K; Oker E; Tomaszewski N; Messerschmidt C; López C; Wagener R; Oehl-Huber K; Dettmer K; Schoeler A; Lenze D; Oefner PJ; Beule D; Siebert R; Capper D; Dimitrova L; Hummel M
BMC Cancer; 2020 May; 20(1):427. PubMed ID: 32408898
[TBL] [Abstract][Full Text] [Related]
16. Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer.
Martínez-Canales S; López de Rodas M; Nuncia-Cantarero M; Páez R; Amir E; Győrffy B; Pandiella A; Galán-Moya EM; Ocaña A
Cancer Med; 2018 May; 7(5):1896-1907. PubMed ID: 29575713
[TBL] [Abstract][Full Text] [Related]
17. Select EZH2 inhibitors enhance viral mimicry effects of DNMT inhibition through a mechanism involving NFAT:AP-1 signaling.
Chomiak AA; Tiedemann RL; Liu Y; Kong X; Cui Y; Wiseman AK; Thurlow KE; Cornett EM; Topper MJ; Baylin SB; Rothbart SB
Sci Adv; 2024 Mar; 10(13):eadk4423. PubMed ID: 38536911
[TBL] [Abstract][Full Text] [Related]
18. Liquid-liquid phase separation of H3K27me3 reader BP1 regulates transcriptional repression.
Tang G; Xia H; Huang Y; Guo Y; Chen Y; Ma Z; Liu W
Genome Biol; 2024 Mar; 25(1):67. PubMed ID: 38468348
[TBL] [Abstract][Full Text] [Related]
19. EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression.
Gonzalez ME; Naimo GD; Anwar T; Paolì A; Tekula SR; Kim S; Medhora N; Leflein SA; Itkin J; Trievel R; Kidwell KM; Chen YC; Mauro L; Yoon E; Andò S; Kleer CG
iScience; 2022 Aug; 25(8):104827. PubMed ID: 35992062
[TBL] [Abstract][Full Text] [Related]
20. Control of endothelial cell function and arteriogenesis by MEG3:EZH2 epigenetic regulation of integrin expression.
Dunn-Davies H; Dudnakova T; Nogara A; Rodor J; Thomas AC; Parish E; Gautier P; Meynert A; Ulitsky I; Madeddu P; Caporali A; Baker A; Tollervey D; Mitić T
Mol Ther Nucleic Acids; 2024 Jun; 35(2):102173. PubMed ID: 38617973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
